Phenotypic and neuropathological heterogeneity in autosomal dominant familial Alzheimer's disease, and implications for amyloid‐immunotherapy
Lecanemab-BS bound to amyloid-β plaques and CAA in cases of ADAD with a variety of mutations and clinical features. The increased lecanemab binding in blood vessels with more severe CAA highlights the need for more sensitive biomarkers of CAA during life and provides further incentive for treating early in the disease.
Authors
- Tammaryn Lashley (ORCID: https://orcid.org/0000-0001-7389-0348)
- Clíona Farrell (ORCID: https://orcid.org/0000-0002-0148-9771)
- Frances K. Wiseman (ORCID: https://orcid.org/0000-0001-9323-3548)
- Natalie S. Ryan (ORCID: https://orcid.org/0000-0003-0361-7455)
- Jasmeer P. Chhatwal (ORCID: https://orcid.org/0000-0002-7792-1698)
- Lei Liu
- Moneeb Nasir
- Ricardo G Pires
- Nanet Willumsen
- Charlotte Burdon
- Nick C Fox
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Escola Superior de Tecnologia da Saúde de Coimbra (PT)
- UK Dementia Research Institute (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
- University of Coimbra (PT)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70857_099386
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00